心悅生醫 | 美體產業公開資訊

心悅生醫與基隆長庚醫院簽署兩項精神分裂症之臨床執行合約·心悅生醫現金增資募集完成，台杉生技基金領投·心悅生醫COVID-19臨床試驗獲台灣衛福部核准執行 ...

We intend to move forward with our human-health focus, leaning towards mental health parity through developing potential treatments for schizophrenia, dementia, and depression.[1]

In terms of COVID-19, I see us addressing this pandemic through a variety of tools, be it traditional Chinese medicines, FDA-approved chemical drugs, or regional-dependent health supplements.

As we forge ahead, we want to always meet these important health issues head on and with an efficient development process. Our goal is to bypass, when it is scientifically sound to do so, the sometimes decade-long delay or billion dollar cost chasm to develop new therapies.